Acumen shares surge 17.55% premarket after appointing George Golumbeski as Chairman, citing his biopharma expertise and strategic collaboration experience.

Acumen Pharmaceuticals (ABOS) surged 17.55% in premarket trading following the announcement that George Golumbeski, Ph.D., was appointed Chairman of its Board of Directors. Golumbeski brings over 30 years of biopharmaceutical expertise, including leadership roles at Celgene, Novartis, and Elan, and is known for strategic collaborations and M&A experience. His appointment aligns with Acumen’s focus on advancing its Phase 2 sabirnetug trial for Alzheimer’s and its Enhanced Brain Delivery program, both seen as key value drivers. The news reinforced investor confidence in the company’s ability to navigate critical development milestones and strengthen its pipeline, positioning Golumbeski’s industry experience as a catalyst for growth and partnerships in the Alzheimer’s therapeutics sector.